Emcure Pharmaceuticals IPO
Emcure pharmaceuticals decided to join the IPO frenzy this year.
IPO Listing Details
- Listing Date
10 Jul 2024
- Listing Price
₹1,325.05
- Listing Change
31.45%
- Last Traded Price
₹1,444.00
IPO Details
- Open Date
03 Jul 2024
- Close Date
05 Jul 2024
- IPO
Price Range
₹ 960 to ₹ 1008
- IPO
Size
₹ 1,952.03 Cr
- Listing Exchange
BSE, NSE
- Listing Date
28 Aug 2024
IPO Timeline
Emcure Pharmaceuticals IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 03-Jul-24 | 0.07 | 2.78 | 1.45 | 1.34 |
| 04-Jul-24 | 0.97 | 13.98 | 3.53 | 5.00 |
| 05-Jul-24 | 191.24 | 49.32 | 7.36 | 67.87 |
Last Updated: 01 August 2024 2:53 PM by 5Paisa
Last Updated: 5th July 2024, 18:15 PM by 5paisa
Emcure Pharmaceuticals IPO is set to open from 3rd July to 5th July 2024. The company develops, manufactures, and markets various pharmaceutical products. The IPO includes a fresh issue of 7,936,507 shares worth ₹800 cr. and an Offer for Sale of 11,428,839 shares worth ₹1,152.03 cr. The total IPO size is ₹1,952.03 cr. The share allotment date is 8th July 2024, and the IPO will be listed on 10th July 2024 on the stock exchanges. The price band is set at ₹960 to ₹1008 and the lot size is 14 shares.
Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and J. P. Morgan India Private Limited are the book-running lead managers for this IPO, while Link Intime India Private Limited is the registrar.
Objectives of Emcure Pharma IPO
● To repay or prepay in full or partial borrowings obtained.
● For general corporate purposes.
Emcure Pharma IPO Video
Emcure Pharma IPO Size
| Types | Size (₹Cr) |
|---|---|
| Total IPO size | 1,952.03 |
| Offer for sale | 1,152.03 |
| Fresh issue | 800.00 |
Emcure Pharma IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,112 |
| Retail (Max) | 14 | 196 | ₹197,568 |
| S-HNI (Min) | 15 | 210 | ₹211,680 |
| S-HNI (Max) | 70 | 980 | ₹987,840 |
| B-HNI (Min) | 71 | 994 | ₹1,001,952 |
Emcure Pharma IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.) |
|---|---|---|---|---|
| QIB | 191.24 | 38,53,234 | 73,68,91,932 | 74,278.71 |
| NII (HNI) | 49.32 | 28,89,926 | 14,25,26,230 | 14,366.64 |
| Retail | 7.36 | 67,43,160 | 4,96,19,010 | 5,001.60 |
| Employees | 8.81 | 1,08,900 | 9,59,742 | 96.74 |
| Total | 67.87 | 1,37,03,538 | 92,99,96,914 | 93,743.69 |
Emcure Pharma IPO Anchor Allocation
| Anchor Bid Date | 2 July, 2024 |
| Total no. of shares offered | 5,779,850 |
| Portion Size for Anchor Investors | 582.61 Cr. |
| Lock in Period for 50% shares (30 days) | 7 August, 2024 |
| Lock in Period for rest of shares (90 days) | 6 October, 2024 |
Established in 1981, Emcure Pharmaceuticals Limited develops, manufactures, and markets various pharmaceutical products. The company’s product portfolio for R&D includes orals, injectables and biotherapeutics. The company has a global reach across 70 countries with a strong presence in India, Europe and Canada. It has a presence in most of the major therapeutic areas, including gynaecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/anti-neoplastics.
It is the largest, 4th largest, and 14th largest company in India in terms of i) gynaecology and human immunodeficiency virus (HIV) antivirals therapeutic areas ii) by market share in our Covered Markets in terms of Domestic Sales for MAT for FY2024 and iii) by Domestic Sales for MAT for FY2024, respectively.
The company has 548 qualified scientists and 5 dedicated R&D facilities in the country along with 220 patents as of FY2024. It also has 13 manufacturing units based in India.
Peer Comparison
● Dr Reddy's Laboratories Limited
● Cipla Limited
● Alkem Laboratories Limited
● Torrent Pharmaceuticals Limited
● Mankind Pharma Limited
● Abbott India Limited
● J. B. Chemicals & Pharmaceuticals Limited
For More Information
Webstory on Emcure Pharmaceuticals IPO
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Revenue from operations | 6658.25 | 5985.81 | 5855.38 |
| EBITDA | 1276.78 | 1220.94 | 1393.38 |
| PAT | 527.57 | 561.84 | 702.55 |
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Total Assets | 7806.16 | 6672.53 | 6063.46 |
| Share Capital | 181.15 | 180.85 | 180.85 |
| Total Borrowings | 4684.39 | 4022.87 | 3949.32 |
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Net cash generated from / (used in) operating activities | 1097.24 | 746.85 | 768.20 |
| Net cash from / (used in) investing activities | -712.51 | -467.68 | -788.79 |
| Net cash flow from / (used in) financing activities | -164.20 | -145.39 | -151.85 |
| Net increase (decrease) in cash and cash equivalents | 220.52 | 133.77 | -172.43 |
Strengths
- The company is well-placed in the domestic Market.
- It has demonstrated the Capabilities of Building Brands.
- It also has a Large, Diversified and Fast-Growing Product Portfolio in International Markets.
- The company also has Strong R&D Capabilities and manufacturing facilities.
- Experienced Board and senior management team.
Risks
- Emcure Pharmaceuticals is subjected to comply with the regulations and quality standards stipulated by various regulators, failing to do so may affect the business operations and reputation.
- Any delay, interruption or reduction in the supply or transportation and cost increase of raw materials, finished products may impact the pricing and disrupt supply of the products and operations.
- There are outstanding legal proceedings involving the company, promoters, subsidiaries, directors and group companies.
- The company may face pricing pressure from customers may affect which in turn would affect the margins and profitability.
- The company is exposed to counterparty risk and may face delay in receiving payments or non-receipt of payments.
in 3
easy steps
Using 5paisa App or
Website
to block Payment
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
FAQs
Emcure IPO opens from 3rd July to 5th July 2024.
The size of Emcure IPO is ₹1,952.03 cr.
To apply for Emcure IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for Emcure IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The price band of Emcure IPO is set at ₹960 to ₹1008 per share.
The minimum lot size of Emcure IPO is 14 shares and the minimum investment required to apply for the IPO is ₹13,440.
The share allotment date of Emcure IPO is 8th July 2024.
The Emcure IPO will be listed on 10th July 2024.
Emcure will use the proceedings from the public issue for:
● To repay or prepay in full or partial borrowings obtained.
● For general corporate purposes.
Contact Information
Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
Phone: +91 20 3507 0033
Email: investors@emcure.co.in
Website: https://www.emcure.com/
Emcure Pharmaceuticals IPO Register
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: emcure.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Emcure Pharmaceuticals IPO Lead Manager
Kotak Mahindra Capital Company Limited
Axis Capital Limited
J.P. Morgan India Private Limited
Jefferies India Private Limited
